论文部分内容阅读
自1958年Rabcn首次报道用人垂体中提取的生长激素(GH)治疗1例垂体性侏儒症获得显效以来,人垂体GH应用的时间超过了四分之一世纪,治疗的患者已逾2万。可是,于1985年连续发现了4例以往用过垂体GH治疗的患者因发生Creutzfeldt-Jokob病(CJD)而死亡,因此在美、英等国,人垂体GH已停止使用。1984年11月,美国1例在六十年代和七十年代用过人垂体GH治疗的21岁患者出现了CJD的症状而死亡,病理检查证实此患者死于该病。1985年4月,美国又有2例用过人GH的病人死于CJD,同时英国也发生一类似病例。这一连串的事件引起了医学界的
Since Rabcn first reported in 1958 that the use of human growth hormone (GH) extracted from the pituitary gland to treat one case of pituitary dwarfism has been markedly effective, the human pituitary GH has been used for more than a quarter of a century and has treated more than 20,000 patients. However, in 1985, 4 cases of patients who had previously been treated with pituitary GH were found to have died due to Creutzfeldt-Jokob disease (CJD). Therefore, in the United States, Britain, and other countries, human pituitary GH has ceased to be used. In November 1984, a 21-year-old patient who had been treated with human pituitary GH in the 1960s and 1970s had CJD symptoms and died. Pathological examination confirmed that the patient died of the disease. In April 1985, another two patients in the United States who had used human GH died in CJD, and a similar case occurred in the United Kingdom. This series of events caused the medical community